Patents Examined by Simon Oh
  • Methods and compositions for the targeted delivery of biologically active agents
    Patent number: 7097857
    Abstract: The present invention relates to a sustained release composition for the targeted delivery of biologically active agents to specific tissues and cells. The composition comprises microparticles containing a biocompatible polymer, a water-soluble polymer and a biologically active agent. In one embodiment, the biologically active agent is an antigen or an immunomodulator. In another embodiment, the biologically is a labile agent. The microparticles have a number median diameter of greater than 20 microns upon administration. The water-soluble polymer is present in the sustained released composition in at least about 20% of the dry weight of the microparticle. The sustained release composition provides for the dissolution of the water-soluble polymer of the composition upon hydration, at a much greater rate than the degradation of the biocompatible polymer.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: August 29, 2006
    Assignee: Alkermes Controlled Therapeutics, Inc.
    Inventors: Mark A. Tracy, David S. Scher
  • Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
    Patent number: 7033582
    Abstract: The present invention involves the administration of Copolymer 1 (glatiramer acetate) to treat inflammatory, non-autoimmune central nervous system (CNS) diseases, alleviate the symptoms thereof, inhibit the activity of matrix metalloproteinases and suppress cytokine production by T lymphocytes.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: April 25, 2006
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: V. Wee Yong, Sophie Chabot
  • Hydroxyapatite based drug delivery implant for cancer treatment
    Patent number: 6767550
    Abstract: A hydroxyapatite based bioresorbable material is incorporated with anti-cancer agents to form an implant used for treatment against cancer. Sustained release of the anti-cancer agents may be achieved after implantation at the targeted sites. The dosage of the anti-cancer agent, the microstructure, morphology, and composition of the bioresorbable material allow control of the release profile. The invented implant may be used for drug delivery, chemotherapy, or gene therapy.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: July 27, 2004
    Assignee: Berkeley Advanced Biomaterials, Inc.
    Inventors: François Y. Génin, Ping Luo, Alekha K. Dash
  • Storage stable thyroxine active drug formulations and methods for their production
    Patent number: 6645526
    Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: November 11, 2003
    Assignee: Mylan Pharmaceuticals, Inc.
    Inventors: Dwight D. Hanshew, Jr., David John Wargo